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Apovincamine and the corresponding co-crystal have been synthesized and characterized by single
crystal XRD, FT-IR, UV, TGA/DSG. Components of the crystalline phase have also been investigated in
terms of their corresponding Hirshfeld surface. In the crystal lattice, a three-dimensional
hydrogen-bonded network is observed in the co-crystal, including the formation of a two-dimensional
molecular scaffold. Hirshfeld surfaces and ﬁngerprint plots indicate that the structures are stabilized
by H  H, CH  p, C–H  O and O–H  N intermolecular interactions. In this work, the co-crystal strategy
has been applied successfully to apovincamine. One important parameter, i.e. solubility in water, has also
been signiﬁcantly improved, which proves to be an important factor for bioavailability. Furthermore,
DSC/TGA analysis indicates that the co-crystal maintains its crystallinity up to 200 C, suggesting a higher
stability of the co-crystal compared to apovincamine.
 2015 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
In the crystalline solid state, the difference between a salt and a
co-crystal is rather subtle [1,2]. This is most notably due to the
unambiguous location of the hydrogen atom. Although subject to
debate, generally accepted literature deﬁnitions in a broadercontext have been implemented: Gilli et al. [3] predicted structural
parameters of salts using the strength of donor–acceptor hydrogen
bonds with DpKa > 3, whereas co-crystals where observed with
DpKa < 3. However, additional factors including the isotopic nat-
ure of the hydrogen, the crystal environment, temperature, and
pressure are all inﬂuencing factors affecting the control of the pro-
ton location in the solid-state.
Traditionally focusing on salt formation [4], the formation of
co-crystals has recently been developed as a potential alternative
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Scheme 1. Structures of alkaloids extracted from Vinca minor Linne.
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Scheme 2. The main hydrogen bonding synthons identiﬁed in the co-crystal.
Table 1
Crystal data and structure reﬁnement for apovincamine and its co-crystal.
Apovincamine Co-crystal
Empirical formula C21H24N2O2 C50H54N4O8
Formula weight 336.42 838.97
Wavelength(A) 0.71073 0.71073
Crystal system Monoclinic Triclinic
Space group P 21 P 1
a (Å) 9.2278(18) 7.2450(14)
b (Å) 9.1475(18) 11.289(2)
c (Å) 10.619(2) 14.240(3)
a () 90 80.07(3)
b () 98.04(3) 78.00(3)
c () 90 71.85(3)
V (Å3) 887.5(3) 1075.3(4)
Z 2 1
T/K 293(2) 293(2)
Density (calculated) (g/
cm3)
1.259 1.296
Absorption coefﬁcient
(mm1)
0.081 0.088
h, k, l (min, max) (11,11), (11,11),
(13,13)
(0,8), (12,13),
(16,17)
Parameters 228 565
F(000) 360 446
Goodness-of-ﬁt on F2 0.993 1.039
Final R indices [I>2r(I)]
CCDC
R1 = 0.0815 R1 = 0.0713
xR2 = 0.1201 xR2 = 0.1925
1021467 1021468
Fig. 1. The overlaid UV spectra of apovincamine.
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properties. In general, pharmaceutical co-crystals [5] are deﬁned
as multi-component crystalline structures composed of an
active pharmaceutical ingredient (API) and co-crystal forming
components that are solid at ambient conditions and bound
via non-covalent interactions [6]. Recently, pharmaceutical
co-crystals have gained a lot of attention due to their ability to
tailor physiochemical properties, particularly solubility, dissolu-
tion, stability and bioavailability. With increasing popularity, the
technique of co-crystallization offers the ability to design new
supramolecular scaffolds with desired functional properties [7–9].Practical applications of indole alkaloids have been employed
for many years and more than 40 compound families have been
isolated from plants ever since. However, the mechanism of active
compounds reﬂected in a variety of protective and/or cognitive
effects is rather complex. In the ﬁeld of indole alkaloids, several
target compounds [10,11] contain an eburnane skeleton, with
examples including vincamine, apovincamine, vincomone and vin-
cadifformine (Scheme 1). The latter can be extracted from Vinca
minor Linne and used in a variety of medical applications, e.g. as
a pharmaceutical against cerebrovascular disease [12].
In recent years much scientiﬁc attention has been devoted to
the study of synthetic routes and biological activities [13] of
vincamine derivatives in an effort to illustrate the further
mechanisms of action and to ﬁnd improved lead compounds with
vasodilatory activity on cerebal blood vessels. Apovincamine
has been demonstrated to exhibit particularly interesting
Fig. 2. Molecular structure of apovincamine, intramolecular hydrogen bonds are in dashed lines and supramolecular synthons around the S11(7) unit (a); crystal packing
stabilized by an obvious C–H  p intermolecular interactions were observed with distance of 3.568 ÅA
0
(b); a two-dimensional network viewed from a-axis (c); the layer
structure viewed from a-axis with the width of 12.001 ÅA
0
(d).
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vincamine and a hypotensive activity remaining mostly unchanged
[14]. It has already been explained in great detail why the extracts
show superior effects over pure vincamine.
Typically, alkaloids with widespread applications include vin-
camine and its derivatives. However, a general disadvantage is that
these compounds show poor water solubility. The purpose of this
work is to apply the co-crystal strategy to apovincamine in an
effort to develop co-crystals with antioxidant features, good
solubility [15] and efﬁcient bioavailability, a feature critical to
pharmaceutical applications in the treatment and/or prevention
of diseases. Furthermore, to study the interaction of apovincamine
with terephthalic acid, we report the synthesis and correspondingcrystal structures of the co-crystals (Scheme 2). The newly
synthesized apovincamine and its co-crystal were screened for
solubility and stability; experimental details of these studies
follow in subsequent sections.Experimental section
General
The corresponding starting material and all reagents were
obtained from commercial sources and were used without further
puriﬁcation. Infrared spectra were recorded on a SHIMADZU IR
Table 2
Geometrical parameters for the hydrogen bonds and C–H  p interactions in apovincamine and its co-crystal.
D–HA D–H (Å) H  A (Å) D  A (Å) <D–H  A (deg) Symmetry code
Apovincamine Inter C14–H14  O1 0.93 2.58 3.100 (5) 116
Co-crystal O2–H2  N2 0.82 1.80 2.592(6) 162 1 + x,y, 1 + z
O3–H3  N4 0.82 1.8 2.603(6) 168 x,1 + y,z
C9–H9  O5 0.93 2.54 3.471(3) 175
Inter C14–H14  O2 0.93 2.45 2.759(5) 100
C19–H19  O9 0.93 2.54 3.464(6) 173
C42–H42A  O2 0.97 2.4 3.338(4) 164 1 + x,y,1 + z
C48–H48b  O3 0.97 2.3 3.241(3) 164 1 + x,y,1 + z
C–H  p H  Cg X  Cg X–H  Cg Symmetry code
Apovincamine C13–H13  Cg(1)a 2.90 3.568(5) 130 1x,1/2 + y, 1z
Co-crystal C14–H14  Cg(27)b 2.88 3.521(3) 127 1 + x,1 + y,1 + z
C28–H28  Cg(23)c 2.70 3.418(2) 134 1 + x,1 + y,1 + z
C49–H49B  Cg(27)b 2.76 3.514(5) 136 1 + x,y,z
C53–H53A  Cg(1)d 2.94 3.776(4) 146 1 + x,y,z
a 6-Membered Ring N(1)? C(3)? C(15)? C(5)? C(11).
b 6-Membered Ring C(20)? C(21)? C(50)? C(40)? C(52)? C(38).
c 5-Membered Ring N(1)? C(2)? C(27)? C(21)? C(20).
d 6-Membered Ring N(3)? C(1)? C(3)? C(7)? C(11)? C(30).
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400–4000 cm1, with all samples analyzed in potassium bromide
pellets. Differential scanning calorimetry (DSC) and thermo gravi-
metric analysis (TGA) were performed using a Mettler-Toledo
TGA/DSC STARe system at a heating rate of 10 Kmin1 under a
dry N2 atmosphere and at a constant ﬂow (20 cm3/min) over a
range from 40 C to 500 C. Samples were placed in open
aluminum oxide crucibles, annealed to 1100 C. The TGA/DSC data
were analyzed using STARe software provided by Mettler-Toledo.
LC–MS analysis was performed on a TSQ Quantum Ultra AM
LC-MS (Thermo Finnigan) with an electrospray ionization source
and operated in the positive (ESI+) mode at 350 C with N2 as
nebulizer. The source temperature was kept at 150 C and the
capillary voltage was maintained at 5.0 kV.
Preparation of apovincamine and its corresponding co-crystal [16,17]
A mixture of vincamine (10 g, 28.2 mmol), p-toluenesulfonic
acid monohydrate (10.7 g, 56.3 mmol) in 100 ml of toluene was
reﬂuxed for 2 h. During this period, any water formed in the reac-
tion was removed by azeotropic distillation using a Marcusson
trap. The progress of the reaction was monitored by thin layer
chromatography (TLC). When the starting materials could no
longer be detected, the solution was cooled to room temperature
and evaporated in vacuo. The dry residue was dissolved in water
and the pH was adjusted to 8 with 5% aqueous sodium hydroxide
solution. After one hour, the separated material was ﬁltered,
washed with 5 ml of ethanol, and dried in vacuo to obtain apovin-
camine (8.6 g, 90%) as a white solid. 1H NMR (500 MHz, CDCl3):
d1.00 (m, 4H), 1.39 (m, 1H), 1.50 (d, J = 15 Hz 1H), 1.72 (m, 1H),
1.87 (m, 2H), 2.50 (m, 1H), 2.60 (t, J = 10 Hz 2H), 2.99 (m, 1H),
3.23 (m, 1H), 3.34 (dd, J = 5 Hz 1H), 3.95 (s, 1H), 4.15 (s, 1H), 6.13
(s, 1H), 7.11 (m, 1H), 7.14 (m, 1H), 7.21(m, 1H), 7.45(m, 1H); 13C
NMR (500 MHz, CDCl3): d8.692, 16.360, 20.285, 27.307, 28.615,
37.746, 44.922, 51.491, 52.465, 55.772, 76.751, 77.006, 77.260,
108.699, 112.414, 118.239, 120.259, 121.958, 128.144, 128.202
129.064, 134.107, 163.854; MS (ESI): required for C21H26N2O2
[M],337.4; found 337.2.
The experimental procedure to obtain single crystals of apovin-
camine is as follows: apovincamine (1 mmol, 338 mg) was dis-
solved in 50 ml acetone; the solution was stirred for 1 h, ﬁltered
and the solvent was allowed to slowly evaporate under ambient
conditions, yielding colorless crystals (Mp: 165.5 C and IR, KBr
pellet, cm1: 3428, 2933, 1727, 1631, 1454, 1280, 1205, 1080,
833, 744, 578, 532, 503, 468, 431).A general experimental procedure for obtaining co-crystal is as
follows: apovincamine (1 mmol, 338 mg) and terephthalic acid
(0.05 mmol, 83 mg) were dissolved in 50 ml methanol; the solu-
tion was stirred for one hour, ﬁltered and the solvent was allowed
to slowly evaporate under ambient conditions to yield colorless
crystals (Mp: 197.0 C and IR, KBr pellet, cm1: 3421, 2962, 1726,
1641, 1457, 1257, 1085, 736, 642, 611, 590, 572, 559, 538, 507,
474, 431).X-ray crystallographic studies
Single crystal X-ray diffraction data was collected at 293 K using
graphite monochromated Mo Ka radiation (k = 0.071073 nm) on
Rigaku’s SCX mini diffractometer with the x-scan technique. The
lattice parameters were integrated using vector analysis and
reﬁned from the diffraction matrix. Absorption corrections were
carried out using the Bruker SADABS program with multi-scan
method. A summary of crystallographic data, data collection, and
reﬁnement parameters is summarized in Table 1. The structural
determination was carried out using the SHELX package. The
structures were solved by direct method, with reﬁnements being
carried out by full-matrix least-square on |F|2 using the
SHELXL-97 program [18,19]. Reliability factors were deﬁned as
R1 = Rw(|F0||Fc|)/R|F0| and the function minimized was
Rw = [Rw(F02Fc2)2/w(F0)4]1/2, whereas in the least-squares calcula-
tion the unit weight was used. All non-hydrogen atoms were
reﬁned anisotropically and hydrogen atoms were inserted at their
calculated positions and ﬁxed at their positions. CCDC [20] refer-
ence numbers 1021467 and 1021468 contain the supplementary
crystallographic data reported in this paper as CIF ﬁles. These data
sets can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/
data_request/cif.Hirshfeld surface calculations
Calculations of Molecular Hirshfeld surfaces [21,22] were per-
formed using the CrystalExplorer program. When the CIF ﬁles were
entered into the CrystalExplorer program, all bond lengths to
hydrogen were automatically modiﬁed to typical standard neutron
values [23] (C–H = 1.083 Å, N–H = 1.009 Å and O–H = 0.983 Å). All
Hirshfeld surfaces were generated using a standard (high) surface
resolution [24]. For a given crystal structure and a set of spherical
atomic electron densities, the Hirshfeld surface is unique. The dnorm
Fig. 3. Molecular structure of co-crystal, the thermal ellipsoid plot at 30% probability and hydrogen bonds between apovincamine molecules and terephthalic acid molecules
(a); hydrogen bonds formed by two apovincamine molecules and supramolecular synthons around the R22(10) dimeric unit (b); an inﬁnite 1D chain motif of a layer viewed
from a-axis (c); crystal packing stabilized by an obvious C–H  p intermolecular interactions were observed with distance of 3.514 ÅA
0
, 3.521 ÅA
0
, 3.418 ÅA
0
and 3.776 ÅA
0
(d).
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a red–blue–white color scheme: red regions represent closer
contacts and a negative dnorm value; blue regions represent longer
contacts and a positive dnorm value; white regions represent the
distance of contacts exactly corresponding to the Van der Waals
separation with a dnorm value of zero. The 3-D dnorm surfaces can
be resolved into 2-D ﬁngerprint plots, analyzing all of the inter-
molecular contacts at the same time to quantitatively summarize
[26,27] the nature and type of all intermolecular contacts experi-
enced by the molecules in the crystal.Solubility studies
An Agilent 1260 HPLC system was used to analyze apovin-
camine and its co-crystal, together with a 1260 variable wave-
length detector (VWD). Before this procedure, an Agilent Eclipse
plus-C18 analytical column (4.6 mm  150 mm, 3.5 lm particle
sizes) was used as a separation column. For apovincamine, the
UV detector was set to a wavelength of 273 nm in order to avoid
any interference from near ultraviolet radiation. The corresponding
spectrum is shown in Fig. 1.
Fig. 4. The terephthalic acid induced conﬁguration change (a); apovincamine molecules (type I and type II) have similar conﬁguration.
92 Y.-h. Ma et al. / Journal of Molecular Structure 1097 (2015) 87–97A mixture of triethylamine 0.5% (pH = 7.5) and methanol
(40:60) was used as the mobile phase. The column temperature
was maintained at 25 C during analysis. Pre-treatment and con-
centration columns were operated at ambient temperature.
Pumps 1 and 2 were used to deliver mobile phase 1 at a ﬂow rate
of 0.40 ml/min and mobile phase 2 at a ﬂow rate of 0.60 ml/min,
respectively. The entire solution was ﬁltered using a 0.45 lm
membrane ﬁlter (Millipore Corp., Bedford) and degassed before
performing HPLC analysis. The system was running at a ﬂow rate
of 1 ml/min and the total time was 60 min. The injection volume
was 10 ll.
Stability
The degradation studies of apovincamine and the correspond-
ing co-crystal were carried out under acid/base hydrolysis and con-
ditions of oxidative stress according to methods previously
published [28–30]. For acid hydrolysis of drug substances, solu-
tions of apovincamine and its co-crystal were treated with 0.1 M
hydrochloric acid in a water bath at 65 C for 2 h. Alkaline hydrol-
ysis was conducted using 0.1 M sodium hydroxide at 65 C for 2 h.Table 3
Geometry parameters of selected bond angle and torsion angle in apovincamine and its c
Apovincamine Apovincamine (type II)
Bond length(Å)
O2–C6 1.454(6) O6–C53
C8–C12 1.515(6) C25–C19
C5–C17 1.519(6) C7–C41
N2–C18 1.480(6) N4–C36
C18–C9 1.525(6) C36–C47
C10–C8 1.552(6) C34–C25
C8–C7 1.566(6) C25–C48
Bond angle ()
C6–O2–C4 117.1(4) C53–O6–C31
C12–C1–N1 119.8(4) C19–C35–N3
C11–C5–C17 119.3(5) C1–C7–C41
N2–C2–C11 109.2(4) N4–C12–C1
C8–C7–C19 115.8(4) C25–C48–C46
Torsion angle ()
O2–C4–C1–C12 41.8(6) O6–C31–C35–C19
O1–C4–C1–N1 33.7(7) O5–C31–C35–N3
C11–C2–C8–C12 42.8(5) C1–C12–C25–C19
C2–C8–C12–C1 31.1(6) C12–C25–C19–C35
C8–C12–C1–N1 2.8(7) C25–C19–C35–N3
C12–C1–N1–C11 12.8(6) C19–C35–N3–C1
C17–C20–N2–C2 64.0(5) C41–C17–N4–C12
C2–N2–C18–C9 49.6(5) C12–N4–C36–C47
C10–C8–C7–C19 55.3(6) C34–C25–C48–C46
C12–C8–C7–C19 66.8(5) C19–C25–C48–C46For studies on oxidative stress, sample solutions in 3% hydrogen
peroxide were kept at 65 C for 2 h. After degradation, the acidic
and alkaline solutions were neutralized by adding proper amounts
of sodium hydroxide or hydrochloric acid which were diluted with
solvent to yield a concentration of 10 lg per ml.Results and discussion
Crystal structures
Apovincamine crystallizes as colorless cuboid-shaped crystals,
representing the P21 space group of a monoclinic system. A sche-
matic ORTEP-drawing of apovincamine with thermal ellipsoids at
30% probability is shown in Fig. 2a. A strong intramolecular
C14–H14  O1 hydrogen bond (distance of 3.100 Å and angle of
116) can be detected forming a cyclic S11 (7) system. C–H  p inter-
molecular interactions have been observed with the distance of
3.568 ÅA
0
(Fig. 2b), exhibiting crucial parameters for the formation
of a network structure. When viewed from the a-axis, a
two-dimensional network is observed in this crystal lattice ando-crystal.
Apovincamine (type I)
1.445(9) O8–C49 1.437(9)
1.505(8) C26–C9 1.534(8)
1.509(8) C27–C44 1.494(8)
1.485(8) N2–C43 1.503(9)
1.531(9) C43–C37 1.504(10)
1.560(8) C15–C26 1.550(9)
1.534(7) C26–C42 1.537(8)
116.1(5) C49–O8–C18 114.8(5)
118.1(5) C9–C23–N1 119.8(5)
120.7(5) C2–C27–C44 122.1(5)
107.8(4) N2–C3–C2 106.7(4)
117.2(5) C26–C42–C54 115.4(6)
144.9(5) O8–C18–C23–C9 144.9(6)
157.4(6) O7–C18–C23–N1 157.1(6)
45.3(6) C2–C3–C26–C9 46.3(6)
33.5(7) C3–C26–C9–C23 34.3(7)
0.5(8) C26–C9–C23–N1 0.8(8)
20.1(8) C9–C23–N1–C2 19.5(8)
65.4(7) C44–C33–N2–C3 66.6(7)
53.6(6) C3–N2–C43–C37 53.3(6)
45.8(8) C15–C26–C42–C54 47.5(8)
75.6(8) C9–C26–C42–C54 74.2(8)
Fig. 5. 3-D dnorm surfaces and 2-D ﬁngerprint plots of apovincamine molecule in two crystals.
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parameters for hydrogen bonds present in apovincamine and its
co-crystal are summarized in Table 2.
The co-crystals also form as colorless cuboid-shaped crystals,
representing the P1 space group of a triclinic system, with the
asymmetric unit (ASU) consisting of one terephthalic acid mole-
cule and two apovincamine molecules. A schematic ORTEP draw-
ing of the co-crystal with thermal ellipsoids at 30% probabilitywas shown in Fig. 3a, in which the terephthalic acid molecule func-
tions as a bridge connecting two apovincamine units through O–
H  N and C–H  O hydrogen bonds. The apovincamine molecule
(type I) and the terephthalic acid molecule formed a dimeric unit
by R22 (7) supramolecular heterosynthon through O–H  N (dis-
tance of 2.592 and angle of 162) and C–H  O (distance of 3.338
Å and angle of 164) hydrogen bond interactions. The apovin-
camine molecule (type II) also formed a dimeric unit by R22 (7)
Table 4
Summary of the various contact contributions to apovincamine molecules in
Hirshfeld surface area.
Apovincamine
(%)
Apovincamine
(type II) (%)
Apovincamine
(type I) (%)
H–H 67.7 63.2 62.5
H–O 12.5 17.4 17.7
C–H 17.4 15.4 17.6
N–H 2.2 1.6 1.5
C–O 0.3 0.2
C–C 1.9 0.3
O–O 0.2 0.2
Fig. 7. Solubility of apovincamine and its co-crystal at different temperature.
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and angle of 168) and C–H  O (distance of 3.241 Å and angle of
164) hydrogen bond interactions. Notable is the fact that these
two pairs of C–H  O and O–H  N hydrogen bonds are almost
identical and not centrosymmetric.
Further analysis reveals that the terephthalic acid molecule
formed a S11 (5) ring through C14–H14  O2 (distance of 2.759
and angle of 100) hydrogen bond interactions. However, between
C13–H13 and O3, no intramolecular hydrogen bond can be
detected. The two apovincamine molecules form a dimeric unit
by R22 (10) supramolecular heterosynthon through C9–H9  O5
(distance of 3.471 Å and angle of 175) and C19–H19  O7 (dis-
tance of 3.464 Å and angle of 173) hydrogen bond interactions
(Fig. 3b). In this crystal lattice, a three-dimensional network can
be observed, which proves to be different from the
two-dimensional network in apovincamine. When viewed from
the a-axis, trimeric units display an inﬁnite 1D chain (Fig. 3c);
the 1D chain stacked across from each other and along the bc
plane; C–H  p intermolecular interactions were observed with
distances of 3.514 ÅA
0
, 3.521 ÅA
0
, 3.418 ÅA
0
and 3.776 ÅA
0
, respectively
(Fig. 3d).
Upon overlay of the three-dimensional structures of the apovin-
camine molecules (Fig. 4), e.g. apovincamine-API and the apovin-
camine molecule (type I and type II), we found that the
apovincamine molecules in the co-crystal maintain a similar con-
ﬁguration, not consistent with the apovincamine structure. For
example, the torsion angle (O5–C31–C35–N3) is found to be
157.35, different from the torsion angle in apovincamineFig. 6. The DSC and TGA proﬁles of a(33.63). Geometry parameters of selected bond angle and torsion
angle in apovincamine and its co-crystal are provided in Table 3.
Hirshfeld surface analysis
The 3D Hirshfeld surfaces of apovincamine molecules in
apovincamine and its co-crystal are shown in Fig. 5a–c; they
clearly show the inﬂuences of co-formers on the intermolecular
interactions of the apovincamine molecule. The large and deep
red spots on the 3D Hirshfeld surfaces indicate the close-contact
interactions, mainly responsible for the corresponding hydrogen
bond contacts. The small red spots on the surfaces represent the
C–H  p interactions. The 2-D ﬁngerprint plots are shown in
Fig. 5d–f, illustrating the breakdown of 2-D ﬁngerprint plots.
With the help of these analysis results, different interactions can
be separated from each other that would commonly overlap in full
ﬁngerprint plots.
For apovincamine (Fig. 5d), the H  H interactions, which are
reﬂected in the middle of scattered points in the 2D ﬁngerprint
plots, exhibit the most signiﬁcant contribution (67.7%) to the totalpovincamine and its co-crystal.
Fig. 8. Chromatogram of apovincamine under different: untreated (a); alkaline hydrolysis (b); oxidation (c).
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interactions appear as two very short spikes in the 2D ﬁngerprint
plots, contributing 12.5%to the total Hirshfeld surfaces. The C–H  p interactions also display a relatively large contribution to
the total Hirshfeld surfaces of apovincamine, totaling 17.4%. The
O–H  N hydrogen bonding interactions did not exhibit signiﬁcant
96 Y.-h. Ma et al. / Journal of Molecular Structure 1097 (2015) 87–97contributions in the 2D ﬁngerprint plots and merely comprise of
2.2% of the total Hirshfeld surfaces. Apart from these main
interactions described above, C–C, C–O and O–O interactions were
not observed, see summarized values in Table 4.
The two types of apovincamine molecules (Fig. 5e and f) display
structurally similar shapes and therefore show similar intermolec-
ular contacts. For the apovincamine molecule (type II), the H  H
interactions also reﬂect the most signiﬁcant contribution to the
total Hirshfeld surfaces, totaling 63.2%. The O–H  N hydrogen
bonding interaction display the second largest contribution to
the total Hirshfeld surfaces, slightly larger than that in apovin-
camine, totaling 17.4%. The third largest contribution can be found
for the C–H  p interactions, totaling 15.4%. For the apovincamine
molecule (type I), the H  H, O–H  N and C–H  p followed the
same order as the apovincamine molecule (type II), resulting in
62.5%, 17.7% and 17.6%. Although the two types of the
apovincamine molecules are very similar, minor differences can
nevertheless be found in the C–H  p and hydrogen bonds.
Further analysis of three types of the apovincamine molecules
revealed an interesting phenomenon: the distance of the C–H  p
interactions corresponding to their corresponding Hirshfeld
surface area contributions follow the order apovincamine
(type II, 3.514 ÅA
0
and 15.4%) < apovincamine (API, 3.568 ÅA
0
and
17.4%) < apovincamine (type I, 3.776 ÅA
0
and 17.6%).
Differential scanning calorimetry (DSC) and thermogravimeric
analysis (TGA)
The DSC and TGA curves of terephthalic acid, apovincamine and
its corresponding co-crystal in a nitrogen atmosphere at a heating
rate of 10 K min1 with a temperature range of 40–400 C are
shown in Fig. 6. For terephthalic acid, the DSC curve shows an
intense endothermic peak at 357.7 C, with a sublimation enthalpy
of 532.3 Jg1. For apovincamine, the melting temperature is
approximately 165.5 C, with a melting enthalpy of 77.61 Jg1.
The TGA curve shows a continued weight loss from 180 C to
400 C with an endothermic enthalpy of 88.47 Jg1. This can be
attributed to the structural decomposition of the apovincamine
molecules. For the co-crystal on the other hand, the TGA curve
shows two endothermic peaks. When the co-crystal begins to dis-
play a weight loss, the DSC curve exhibits an endothermic peak atN
N
O
O
HO
O
Chemical Fo
Molecula
N
N
O
O
N
O
O OH
Chemical Formula: C
Molecular Weight
a
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Scheme 3. The suggested pathway for the degra197 C with a melting enthalpy of 50.63 Jg1. Another endothermic
peak appears at 298.3 C, with a melting enthalpy of 265.31 Jg1.
The results of the DSC and TGA analysis both indicate that the
co-crystal maintains its relative crystallinity up to 200 C, suggest-
ing that the co-crystal also exhibits a better stability than
apovincamine.
Solubility studies
Solubility reﬂects an important parameter for bioavailability
estimations. High Performance Liquid Chromatography (HPLC) in
general displays major advantages in terms of sensitivity and
speciﬁcity and was therefore used to investigate the solubility of
apovincamine and its co-crystal. Prior to solubility measurements,
stock solutions of apovincamine (1 mg/ml) were prepared in
methanol, together with a series of dilutions. The mobile phase
has been adjusted to 0, 0.2 0.4, 0.6, 0.8 mg/ml in an effort to obtain
the corresponding working standards for the preparation of the
standard curve. Then, saturated solutions of apovincamine and
its co-crystal were prepared and measured by HPLC. The results
of the solubility measurements were obtained through the stan-
dard curve.
Using this method, the solubility of apovincamine has been
determined to be 5.5 mg/ml in CH3OH at 30 C, while the solubility
of the co-crystal in the same solvent has been determined to be
9.8 mg/ml and the solubility of pure apovincamine under the same
conditions has been determined to be 7.8 mg/ml. The solubility of
apovincamine and its co-crystals at different temperature are
shown in Fig. 7. Additionally, we found that through the
co-crystal strategy we could further improve the solubility in
CH3OH by 25%. To ﬁnd use as a injectable drug and to yield maxi-
mum dosage, the solubility of apovincamine in water is a very
important parameter. Neat apovincamine could not be dissolved
in water, whereas the co-crystal exhibits good solubility. The
co-crystal strategy could therefore be an elegant way to solve this
solubility problem in a favorable fashion.
Stability studies
Both apovincamine and its co-crystal were not found to be
labile to acid hydrolysis in 0.1 M HCl at 65 C. The experimental
results obtained provide direct evidence for the hypothesis thatN
N
rmula: C20H22N2O2
r Weight: 322.40
N + N N
O
O O
21H26N2O3
: 354.44
Chemical Formula: C21H24N2O3
Molecular Weight: 352.43
tR=4.06 min tR=11.07 min
H
H
dation in 0.1 M NaOH (a) and 3% H2O2 (b).
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camine. However, apovincamine and its co-crystal have been
shown to be highly labile to alkaline hydrolysis: around 36.7%
degradation of apovincamine has been observed in 0.1 M NaOH
at 65 C and within 2 h. The degradation peaks appeared at tR
1.29 min and similar degradation has been observed in the
co-crystal (Fig. 8b). HPLC analysis revealed that the rate of degra-
dation increased with time. The structural characteristics have
been conﬁrmed the LC–MS analyses. The mass of the degradation
product was found to be m/z 323.17 [M + H]+ which corresponds
to the mass of apovincaminic acid. The presumed degradation
pathway in 0.1 M NaOH is shown in Scheme 3a.
The co-crystal was found to be relatively stable upon exposure
to oxidative conditions (e.g. 3% H2O2 at 65 C for 2 h), the presence
of any degradation product (>1/1000) could not be detected by
HPLC. Neat apovincamine on the other hand was found to be prone
to oxidation under these condition, resulting in about 10% degrada-
tion. Two major peaks corresponding to the degradation product
appeared at tR 4.06 min and 11.07 min (Fig. 8c). LC-MS analysis
revealed the molecular mass of the degradation products at m/z
355.3 [M + H]+ and 353.6 [M + H]+. The presumed degradation
pathway is shown in Scheme 3b.
Conclusions
In summary, we have presented the synthesis, crystal structure,
Hirshfeld surface, IR spectra, thermal analysis (DSC and TGA) of
apovincamine and its corresponding co-crystal. The results of the
Hirshfeld surface and crystal structure analysis in particular offer
detailed insights into the intermolecular interactions and the kinds
of interactions providing signiﬁcant contributions to the stability
of the structures. Furthermore, the stability analysis results show
that the co-crystal offers improved physical properties and a com-
bination of theoretical and experimental methods suggest that a
close connection between structure and stability can be noted.
High stability tends to favor the co-crystal with more hydrogen
bonds being present. Apart from the analyses described above,
another relevant parameter could be improved; by employing
the co-crystal strategy, the solubility in water could be improved
signiﬁcantly. The latter is an important factor for bioavailability
and potential medical applications of this family of compounds.
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